EP1180937A1 - Bakteriophagenstämme zur behandlung von vancomycin-resistentem enterococcus faecium infizierten patenten - Google Patents

Bakteriophagenstämme zur behandlung von vancomycin-resistentem enterococcus faecium infizierten patenten

Info

Publication number
EP1180937A1
EP1180937A1 EP00931911A EP00931911A EP1180937A1 EP 1180937 A1 EP1180937 A1 EP 1180937A1 EP 00931911 A EP00931911 A EP 00931911A EP 00931911 A EP00931911 A EP 00931911A EP 1180937 A1 EP1180937 A1 EP 1180937A1
Authority
EP
European Patent Office
Prior art keywords
phage
enterococcus faecium
vancomycin
enb6
pta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00931911A
Other languages
English (en)
French (fr)
Other versions
EP1180937A4 (de
Inventor
Carl R. National Inst. of Mental Health MERRIL
Richard M. Carlton
Sankar Adhya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Exponential Biotherapies Inc
Original Assignee
National Institutes of Health NIH
Exponential Biotherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH, Exponential Biotherapies Inc filed Critical National Institutes of Health NIH
Publication of EP1180937A1 publication Critical patent/EP1180937A1/de
Publication of EP1180937A4 publication Critical patent/EP1180937A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10311—Siphoviridae
    • C12N2795/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Definitions

  • MDR Enterococcus faecium
  • MDR multidrug resistant
  • Synercid® recently entered the market as a treatment for vancomycin-resistant bacteria, including VREF.
  • MDR bacteria are so efficient at resisting newer antibiotics (even those to which
  • efflux pump can transport out many classes of drugs; and a mutation in the
  • ribosomal subunit targeted by antibiotics can defeat several classes of drugs.
  • Bacte ophage (phage) therapy offers one such alternative.
  • phage strains for example ENB6
  • phages tend to be rapidly cleared from the systemic circulation by the filtering action
  • the technique also selects for those mutants that retain their ability to lyse the target
  • phage stains that attack VREF hosts have
  • Phage strains were grown by standard techniques known in the art,
  • the ENB6 genome contains at least 120 kb of DNA as determined by
  • nucleotide sequence has been defined at 99% confidence, while 24.7 kb has been defined at a lower level of confidence. The remaining amount is presently
  • ENB6 nucleotide sequences have been compared to all genes and
  • Figure 2 is an electron microscopic picture of phage ENB6.
  • the routes of administration include but are not limited to: oral, aerosol or
  • intrathecal intraperitoneal, intrathecal, vaginal, rectal, topical, lumbar puncture, intrathecal,
  • the free phage could be in lyophilized form and be
  • administration is contemplated to be in the range of about 10 3 to about 10 13
  • the phage are Table 2. Proteins screened by PCR amplification of ENB6 DNA.
  • the present invention will be particularly useful in treating critically ill
  • ENB6 ATCC # PTA-40
  • ENB13 ATCC # PTA-39
  • Figures 3 and 4 show the results of a dose-finding study.
  • CRMEN44 is 1 x 10 9 CFU, when injected I. P. into one month-old balb/c
  • PFU plaque forming units PFU
  • the non-parametric rating scale for observable signs of illness is as follows:
  • Phage administered as a control did not produce any detectable symptoms in the
  • Phage ENB6 rescues animals from an otherwise-fatal dose of VREF, a bacterial
  • Figures 5 and 6 show the results of delay in the treatment of a fulminant
  • VREF are orders-of-magnitude lower than the concentrations achieved here, so it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
EP00931911A 1999-05-13 2000-05-12 Für die rettung von mit vancomycin-resistentem enterococcus faecium infizierten patenten verwendbarer bakteriophagenstamm Withdrawn EP1180937A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13405599P 1999-05-13 1999-05-13
US134055P 1999-05-13
PCT/US2000/006718 WO2000069269A1 (en) 1999-05-13 2000-05-12 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium

Publications (2)

Publication Number Publication Date
EP1180937A1 true EP1180937A1 (de) 2002-02-27
EP1180937A4 EP1180937A4 (de) 2004-08-04

Family

ID=22461568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00931911A Withdrawn EP1180937A4 (de) 1999-05-13 2000-05-12 Für die rettung von mit vancomycin-resistentem enterococcus faecium infizierten patenten verwendbarer bakteriophagenstamm

Country Status (5)

Country Link
EP (1) EP1180937A4 (de)
JP (1) JP2002543816A (de)
AU (1) AU4971900A (de)
CA (1) CA2373486A1 (de)
WO (1) WO2000069269A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030009338A (ko) 2000-01-11 2003-01-29 인트랄리틱스, 인크. 생복합체를 제조하기 위해 생분해성 매트릭스로 사용되는중합체 블렌드
US6759229B2 (en) 2001-12-18 2004-07-06 President & Fellows Of Harvard College Toxin-phage bacteriocide antibiotic and uses thereof
GB0209680D0 (en) * 2002-04-27 2002-06-05 Univ Strathclyde Immobilisation and stabilisation of bacteriophage
US7588929B2 (en) 2002-12-09 2009-09-15 Phage Biopharm Llc Production of bacteriophage compositions for use in phage therapy
DE10342071B4 (de) * 2003-09-10 2006-01-19 Fleischmann, Wilhelm, Dr.med. Vorrichtung und Verfahren zur Applikation von Wïrkstoffen an eine Wundoberfläche
US8178087B2 (en) 2006-04-04 2012-05-15 Centre National de la Recherche Scientifique —CNRS Process of production of bacteriophage compositions and methods in phage therapy field
KR100958139B1 (ko) * 2008-03-31 2010-05-18 주식회사 인트론바이오테크놀로지 엔테로코쿠스 패칼리스 특이적 사멸능을 갖는 신규한박테리오파지
KR100988771B1 (ko) * 2008-09-29 2010-10-20 주식회사 인트론바이오테크놀로지 엔테로코쿠스 및 스트렙토코쿠스 특이적 사멸능을 갖는 신규한 리신 단백질
PL215522B1 (pl) 2008-09-29 2013-12-31 Inst Immunologii I Terapii Doswiadczalnej Pan Nowe szczepy bakteriofagów do leczenia zakazen bakteryjnych, zwlaszcza szczepami bakterii lekoopornych rodzaju Enterococcus
US9134312B2 (en) * 2009-02-06 2015-09-15 Tecnifar—Industria Tecnica Farmaceutica, S.A. Antibacterial phage, phage peptides and methods of use thereof
WO2017177196A1 (en) 2016-04-08 2017-10-12 The Trustees Of Princeton University Novel antimicrobial compositions and methods of use
KR101957266B1 (ko) * 2017-02-22 2019-03-13 주식회사 인트론바이오테크놀로지 엔테로코쿠스 패슘에 대하여 용균력을 가지는 신규한 항균단백질 efal-2
KR101822812B1 (ko) 2017-02-22 2018-01-29 주식회사 인트론바이오테크놀로지 신규한 엔테로코쿠스 패슘 박테리오파지 Ent-FAP-4 및 이의 엔테로코쿠스 패슘 증식 억제 용도
GB201712733D0 (en) 2017-08-08 2017-09-20 Snipr Tech Ltd Methods & cells
KR102203679B1 (ko) * 2018-12-26 2021-01-15 주식회사 옵티팜 신규한 엔테로코커스 패시움 균 특이 박테리오파지 ef44 및 이를 포함하는 항균 조성물
GB201901099D0 (en) 2019-01-27 2019-03-13 Snipr Biome Aps Methods, uses and compositions
EP4355345A1 (de) * 2021-06-15 2024-04-24 Ferring B.V. Bakteriophagen gegen vancomycin-resistente enterokokken
WO2024003301A1 (en) 2022-06-29 2024-01-04 Snipr Biome Aps Targeting e coli cells
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766892A (en) * 1994-04-05 1998-06-16 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766892A (en) * 1994-04-05 1998-06-16 Exponential Biotherapies, Inc. Antibacterial therapy with bacteriophage genotypically modified to delay inactivation by the host defense system together with an antibiotic

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALISKY J ET AL: "BACTERIOPHAGE SHOW PROMISE AS ANTIMICROBIAL AGENTS" JOURNAL OF INFECTION, ACADEMIC PRESS, LONDON, GB, vol. 36, 1998, pages 5-15, XP000993238 ISSN: 0163-4453 *
See also references of WO0069269A1 *

Also Published As

Publication number Publication date
WO2000069269A9 (en) 2002-02-21
AU4971900A (en) 2000-12-05
WO2000069269A1 (en) 2000-11-23
JP2002543816A (ja) 2002-12-24
EP1180937A4 (de) 2004-08-04
CA2373486A1 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
WO2000069269A1 (en) Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
Nishikawa et al. T-even-related bacteriophages as candidates for treatment of Escherichia coli urinary tract infections
Jalava et al. Use of the polymerase chain reaction and DNA sequencing for detection of Bartonella quintana in the aortic valve of a patient with culture-negative infective endocarditis
US5811093A (en) Bacteriophage genotypically modified to delay inactivations by the host defense system
US11492378B2 (en) Antibacterial protein EFAL-2 having bacteriolytic ability with respect to Enterococcus faecium
JP7449967B2 (ja) 療法バクテリオファージ組成物
CN112218659A (zh) 用于治疗葡萄球菌感染的治疗性噬菌体组合物
US20010043924A1 (en) Antibacterial therapy with bacteriophage physico-chemically altered to delay inactivation by the host defense system
AU2004200450B2 (en) Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium
WO2004020635A1 (ja) バクテリオファージおよび細菌感染症治療剤
KR102510118B1 (ko) 큐티박테리움 애크니스에 대한 사멸능을 갖는 박테리오파지 cap-1
WO2019191508A1 (en) Biomarker and treatment target for alcoholic hepatitis
WO2023288334A1 (en) Method of treating drug resistant eskape pathogens using therapeutic bacteriophages
WO2017178561A1 (en) A bacteriophage strain capable of producing a lytic infection in the escherichia coli st131-o25b:h4 clone
CN115038799A (zh) 治疗细菌感染的方法
US20240189373A1 (en) Bacteriophage compositions for treating staphylococcus infection
EP3440200B1 (de) Modifizierter bakteriophage
Popa PROMISING EXPECTATIONS FROM PHAGE DEPOLYMERASES FOR CHALLENGING KLEBSIELLA PNEUMONIAE VIRULENCE
CN115725607A (zh) 一种鼻疽诺卡菌的致病靶基因及其应用
KR20230159558A (ko) 장독소원성 박테로이데스 프라길리스의 증식을 억제하기 위한 조성물 및 방법
Sahni Review on Phage Therapy
Godány et al. Phage therapy: Alternative approach to antibiotics
Lin et al. Isolation of a bacteriophage and its depolymerase specific for K1 capsule of Klebsiella

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011212

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040623

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20051201